Posted by Michael Wonder on 06 Nov 2024
Journey Medical announces US FDA approval of Emrosi (minocycline hydrochloride extended release capsules, 40 mg) for the treatment of rosacea
4 November 2024 - Journey Medical today announced that the FDA has approved Emrosi (minocycline hydrochloride extended release capsules, 40 mg), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults.
Emrosi was developed in collaboration with Dr. Reddy’s Laboratories.
